OTraces` New Cancer Detection Technology Goes Beyond Liquid Biopsy (ver. April 20, 2018) - Video

OTraces has developed a patented technology to enhance the accuracy of cancer detection and surveillance with a simple blood test, currently for prostate cancer and breast cancer. Going beyond the current liquid biopsy technology, OTraces' blood test s biomarker agnostic and utilizes ordinary ELISA instrumentation. It is the first test to achieve access to active proteins found in the tumor microenvironment (TME) --- well recognized as the prime center of diagnostic content and as the focal point for immunotherapy drug and vaccine development. The TME blood test enables OTraces to diagnose tumor status and progression dynamically and in real time, without the need for an expensive and often traumatic biopsy in most cases.